Eribulin (Halaven)

==General information==
Class/mechanism: Non-taxane microtubule dynamics inhibitor. Inhibits the growth phase of microtubules and aggregates tubulin into inactive aggregates. Does not affect the shortening phase. Disruption of mitotic spindles interferes with mitosis, leads to G2/M cell-cycle block, and apoptotic cell death.Eribulin (Halaven) package insert Eribulin (Halaven) package insert (locally hosted backup)Halaven manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Breast cancer
*Soft tissue sarcoma
**Leiomyosarcoma
**Liposarcoma
==Patient drug information==
*Eribulin (Halaven) package insert 
*Eribulin (Halaven) patient drug information (Chemocare)Eribulin (Halaven) patient drug information (Chemocare)
*Eribulin (Halaven) patient drug information (UpToDate)Eribulin (Halaven) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2010-11-15: Initial approval for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (Based on EMBRACE)
* 2016-01-28: Approved for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (Based on E7389-G000-309)
==History of changes in EMA indication==
*2011-03-17: Initial marketing authorization as Halaven.
*Uncertain date: Indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. 
*Uncertain date: Indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
==History of changes in Health Canada indication==
*2011-12-14: Initial notice of compliance for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane administered in either the adjuvant or metastatic setting.
*2017-08-04: New indication for the treatment of adult patients with an unresectable advanced or metastatic liposarcoma subtype of soft tissue sarcoma. Prior therapy should have included an anthracycline-containing regimen, unless not clinically appropriate.
==History of changes in PMDA indication==
*2011-04-22: Initial approval for the treatment of inoperable or recurrent breast cancer.
*2016-02-29: New additional indication for the treatment of soft tissue sarcoma.
==Also known as==
*Code names: E-7389, ER-086526, NSC-707389
*Generic name: eribulin mesylate
*Brand name: Brutravon, Ceribulin, Ebunat, Embremma, Epbriv, Evaira, Halaven, Mevlyq, Mitobulin, Rayldeima, Teceris
==References==
Category:Drugs
Category:Intravenous medications
Category:Microtubule inhibitors
Category:Breast cancer medications
Category:Leiomyosarcoma medications
Category:Liposarcoma medications
Category:Soft tissue sarcoma medications
Category:EMA approved in 2011
Category:FDA approved in 2010
Category:Health Canada approved in 2011
Category:PMDA approved in 2011